Remdesivir
FDA-approved product (powder, intravenous), marketed as Veklury.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Coronavirus infectious disease
- COVID-19
- Severe acute respiratory syndrome
- Viral disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Nucleosides and nucleotides excl. reverse transcriptase inhibitors
- FDA pharmacologic class
- SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor FDA label ↗
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AB16
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Remdesivir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780463 · start 2021-06-11
Registered record
- Registry ID
- NCT05780463
- Conditions
- COVID-19
- Interventions
- MP0420; Placebo; Remdesivir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2021-06-11
- Completion
- 2023-06-08
- Enrolment
- 485
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOVID-19InterventionMP0420; Placebo; RemdesivirPhasePhase 3Registry statusCompletedTrial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
NCT04784559 · start 2021-06-04
Registered record
- Registry ID
- NCT04784559
- Conditions
- COVID-19 Infection
- Interventions
- Plitidepsin; Dexamethasone; Remdesivir; Favipiravir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2021-06-04
- Completion
- 2023-03-01
- Enrolment
- 205
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOVID-19 InfectionInterventionPlitidepsin; Dexamethasone; Remdesivir; FavipiravirPhasePhase 3Registry statusTerminatedWorld Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
NCT04647669 · start 2021-06-01
Registered record
- Registry ID
- NCT04647669
- Conditions
- Covid19
- Interventions
- Remdesivir; Acalabrutinib; Interferon beta-1a; Standard of Care
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2021-06-01
- Completion
- 2021-12-31
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCovid19InterventionRemdesivir; Acalabrutinib; Interferon beta-1a; Standard of CarePhasePhase 3Registry statusUnknownLow-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot Study
NCT04904783 · start 2021-06-01
Registered record
- Registry ID
- NCT04904783
- Conditions
- COVID-19; Pneumonia
- Interventions
- Low dose radiotherapy
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2021-06-01
- Completion
- 2021-12-31
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOVID-19; PneumoniaInterventionLow dose radiotherapyPhaseNot applicableRegistry statusUnknownStudy to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
NCT04672564 · start 2021-03-30
Registered record
- Registry ID
- NCT04672564
- Conditions
- Coronavirus Disease 2019
- Interventions
- Carrimycin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2021-03-30
- Completion
- 2022-05-09
- Enrolment
- 93
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronavirus Disease 2019InterventionCarrimycin; PlaceboPhasePhase 3Registry statusTerminatedSARS-CoV-2 Human Challenge Characterisation Study
NCT04865237 · start 2021-03-06
Registered record
- Registry ID
- NCT04865237
- Conditions
- Covid19; SARS-CoV Infection; Corona Virus Infection; Coronavirus; COVID-19
- Interventions
- SARS-CoV-2 Virus 1x10^1 TCID50; Remdesivir; SARS-CoV-2 Virus 1x10^2 TCID50; SARS-CoV-2 Virus 1x10^3 TCID50
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2021-03-06
- Completion
- 2022-07-11
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCovid19; SARS-CoV Infection; Corona Virus Infection; Coronavirus +1 moreInterventionSARS-CoV-2 Virus 1x10^1 TCID50; Remdesivir; SARS-CoV-2 Virus 1x10^2 TCID50; SARS-CoV-2 Virus 1x10^3 TCID50PhaseNot applicableRegistry statusCompletedEfficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients
NCT04713176 · start 2021-02-02
Registered record
- Registry ID
- NCT04713176
- Conditions
- Severe COVID-19
- Interventions
- DWJ1248 with Remdesivir; Placebo with Remdesivir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2021-02-02
- Completion
- 2022-12-09
- Enrolment
- 240
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSevere COVID-19InterventionDWJ1248 with Remdesivir; Placebo with RemdesivirPhasePhase 3Registry statusTerminatedEvaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip
NCT04980534 · start 2021-01-08
Registered record
- Registry ID
- NCT04980534
- Conditions
- Covid19; COVID-19 Pneumonia; COVID-19 Respiratory Infection; Viral Infection; Respiratory Tract Infections; Infection, Coronavirus; SARS-CoV2 Infection
- Interventions
- Viusid and Asbrip; COVID-19 Standard Therapy
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2021-01-08
- Completion
- 2021-09-15
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCovid19; COVID-19 Pneumonia; COVID-19 Respiratory Infection; Viral Infection +3 moreInterventionViusid and Asbrip; COVID-19 Standard TherapyPhaseNot applicableRegistry statusCompletedFirst-in-Human Study of Orally Administered GS-441524 for COVID-19
NCT04859244 · start 2021-01-01
Registered record
- Registry ID
- NCT04859244
- Conditions
- COVID-19
- Interventions
- GS-441524
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2021-01-01
- Completion
- 2021-08-01
- Enrolment
- 1
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOVID-19InterventionGS-441524PhasePhase 1Registry statusCompletedCombination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19
NCT05279391 · start 2020-10-25
Registered record
- Registry ID
- NCT05279391
- Conditions
- COVID-19 Severe Respiratory Failure
- Interventions
- Dexamethasone; Low molecular weight heparin; Anakinra 100Mg/0.67Ml Inj Syringe; Tocilizumab; Baricitinib; Dornase Alfa Inhalant Product
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2020-10-25
- Completion
- 2023-12-31
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOVID-19 Severe Respiratory FailureInterventionDexamethasone; Low molecular weight heparin; Anakinra 100Mg/0.67Ml Inj Syringe; Tocilizumab +2 morePhaseNot applicableRegistry statusUnknownACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19
NCT04583956 · start 2020-10-23
Registered record
- Registry ID
- NCT04583956
- Conditions
- COVID-19
- Interventions
- Placebo; Remdesivir; Risankizumab
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2020-10-23
- Completion
- 2021-09-13
- Enrolment
- 214
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOVID-19InterventionPlacebo; Remdesivir; RisankizumabPhasePhase 2Registry statusCompletedImmune Modulators for Treating COVID-19
NCT04593940 · start 2020-10-15
Registered record
- Registry ID
- NCT04593940
- Conditions
- Covid19
- Interventions
- Infliximab; Abatacept; Remdesivir; cenicriviroc (closed to enrollment as of 3-Sep-2021)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2020-10-15
- Completion
- 2022-03-05
- Enrolment
- 1,971
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCovid19InterventionInfliximab; Abatacept; Remdesivir; cenicriviroc (closed to enrollment as of 3-Sep-2021)PhasePhase 3Registry statusCompletedREMdesivir-HU Clinical Study and Severe Covid-19 Patients
NCT04610541 · start 2020-10-12
Registered record
- Registry ID
- NCT04610541
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Remdesivir-HU
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2020-10-12
- Completion
- 2021-11-30
- Enrolment
- 2,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSARS-CoV-2 InfectionInterventionRemdesivir-HUPhasePhase 3Registry statusUnknownInpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
NCT04546581 · start 2020-10-08
Registered record
- Registry ID
- NCT04546581
- Conditions
- COVID; COVID-19; SARS-CoV-2; SARS (Severe Acute Respiratory Syndrome)
- Interventions
- Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG); Placebo; Remdesivir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2020-10-08
- Completion
- 2021-05-21
- Enrolment
- 593
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCOVID; COVID-19; SARS-CoV-2; SARS (Severe Acute Respiratory Syndrome)InterventionHyperimmune immunoglobulin to SARS-CoV-2 (hIVIG); Placebo; RemdesivirPhasePhase 3Registry statusCompletedSafety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
NCT04480333 · start 2020-09-15
Registered record
- Registry ID
- NCT04480333
- Conditions
- Covid19; Corona Virus Infection; Severe Acute Respiratory Syndrome; Severe Acute Respiratory Infection; Severe Acute Respiratory Syndrome (SARS) Pneumonia; Severe Acute Respiratory Syndrome of Upper Respiratory Tract; Neurodegeneration; Neuroinflammatory Response
- Interventions
- Drug: NA-831 - 0.10 mg/kg; Placebo- 0.10 mg/kg; Drug: NA-831 - 0.20 mg/kg; Placebo- 0.20 mg/kg; Drug: GS-5734 - 1.00 mg/kg; Placebo- 1.00 mg/kg; Drug: GS-5734 - 2.00 mg/kg; Placebo- 2.00 mg/kg; Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg); Placebo 0.10 mg + 1.00 mg/kg; Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg); Placebo 0.20 mg + 2.00 mg/kg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Unknown
- Start
- 2020-09-15
- Completion
- 2021-03-31
- Enrolment
- 45
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCovid19; Corona Virus Infection; Severe Acute Respiratory Syndrome; Severe Acute Respiratory Infection +4 moreInterventionDrug: NA-831 - 0.10 mg/kg; Placebo- 0.10 mg/kg; Drug: NA-831 - 0.20 mg/kg; Placebo- 0.20 mg/kg +8 morePhasePhase 1Registry statusUnknown